Evidence map›Paper›PMID 41181601›Full record

ArticleFrontiers in pharmacology2025

GEODE: an

Maral Budak, Mariana Pereira Moraes, Talia Greenstein, Pauline Maiello, H Jacob Borish, Harris B Chishti, Kara Kracinovsky, Mark Rodgers, Jaime Tomko, Philana Ling Lin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maral BudakDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, United States.
Mariana Pereira MoraesDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, United States.
Talia GreensteinDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, United States.
Pauline MaielloDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
H Jacob BorishDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Harris B ChishtiDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Kara KracinovskyDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Mark RodgersDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Jaime TomkoDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Philana Ling LinDepartment of Pediatrics, Children's Hospital of the University of Pittsburgh of UPMC, Pittsburgh, PA, United States.
JoAnne L FlynnDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States.
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, United States.
Denise KirschnerDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tuberculosis (TB) remains the primary cause of death due to infectious disease in the world. TB, while treatable, requires an extended course of multiple antibiotics, taking 6-9 months, and many antibiotic regimens have deleterious side effects. Treatment is complicated by co-infection, emerging drug resistance, and compliance issues; accordingly, the identification of new and optimal regimens has been a recent focus. Rodent models of TB (e.g., mouse, rabbit) do not mimic some severe pathologies well, while nonhuman primate models are costly. Several computational and Methods: Here we briefly review existing tools and introduce a novel, integrated approach combining Results: We find that Discussion: This work provides a novel tool that can be used to quickly and efficiently evaluate drug regimens for TB.

Indexed as

checkerboardDiaMONDdrug rankingsGranSimPK/PD

Identifiers

PMID41181601
PMCPMC12575316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.